Rivus Pharmaceuticals key facts
as of Oct 2026- Developer of controlled metabolic accelerators designed to improve cardio-metabolic health.
- Rivus Pharmaceuticals is valued at approximately $489.0M as of Oct 2026, set at its later-stage round, Jan 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $224.0M across 4 recorded rounds; the latest was Later Stage VC ($57.0M) in Jan 2025.
- Notable investors include RA Capital Management, Longitude Capital, Bain Capital Life Sciences, BB Biotech, Medicxi — 6 tracked in total.
- Rivus Pharmaceuticals has filed 4 Form Ds with the SEC since 2021, most recently Jan 2025 ($57.0M sold to 7 investors).
- Status: Privately Held (backing).
Valued at $489.0M at its later-stage round, Jan 2025. Nothing has traded since.
- ·Watch Rivus Pharmaceuticals: the Monday email on marks, rounds and moves
Rivus Pharmaceuticals funding rounds
4 roundsWho backs Rivus Pharmaceuticals
6Rivus Pharmaceuticals valuation
Rivus Pharmaceuticals was valued at $489 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Rivus Pharmaceuticals raised?
Rivus Pharmaceuticals has raised $224 million across 4 recorded rounds since 2019. The largest was a $66 million later-stage round in Aug 2024; the most recent was a $57 million later-stage round in Jan 2025.
Rivus Pharmaceuticals has filed 4 Form Ds with the SEC since 2021, most recently in Jan 2025 ($57 million sold to 7 investors).
Rivus Pharmaceuticals investors
6 investors are on record for Rivus Pharmaceuticals, including RA Capital Management, Longitude Capital, Bain Capital Life Sciences and BB Biotech. The later-stage round in Jan 2025 drew 7 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Electra Therapeutics ($479 million), CORXEL Pharmaceuticals ($475 million) and Diagonal Therapeutics ($459 million).
About Rivus Pharmaceuticals
Developer of controlled metabolic accelerators designed to improve cardio-metabolic health. The company improves cellular metabolism and treats the underlying cause of highly prevalent metabolic and cardiovascular diseases, enabling patients with oral small-molecule therapeutics that address the underlying metabolic risk factors for cardiovascular mortality and morbidity.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Charlottesville, VA, United States
- Founded
- 2019
- Employees
- 27
- Website
- rivuspharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.